Illumina (ILMN) Stock Price
Illumina Price
Over the last 19 years Illumina grew revenue by 18.1% annually, reaching 4.34 B USD. Earnings per share have grown at 14.9% per year over the last 19 years. For Illumina, the net margin of 19.6% is up versus 16.8% a few years ago. The consensus 12-month price target for Illumina is 210.00 USD, about 21.7% below where the stock trades today. Of 28 analysts, 16 rate the stock a buy — an overall Buy consensus.
Illumina stock price
Illumina business model & stock analysis
Frequently asked questions about Illumina
The business model of Illumina Inc focuses on developing and selling genetic sequencing and array-based solutions. Illumina specializes in the research, clinical, and applied markets and offers a wide range of products and services. Their innovative technologies enable researchers to sequence DNA, RNA, and whole genomes efficiently and accurately, facilitating various applications in genomics. By providing exceptional sequencing platforms, consumables, and data analysis tools, Illumina aims to empower scientists worldwide to unlock the power of the genome. With a strong commitment to advancing precision medicine, Illumina plays a significant role in catalyzing breakthrough discoveries and contributing to various scientific and medical advancements.
Illumina Inc is primarily active in the biotechnology industry.
The main competitors of Illumina Inc in the market include companies like Thermo Fisher Scientific, Pacific Biosciences, and Oxford Nanopore Technologies.
Illumina Inc. is a renowned genomics company with a rich history and background. Founded in 1998, Illumina has consistently been at the forefront of genomic research and has played a vital role in advancing the field of genetic sequencing. The company specializes in developing innovative technologies and solutions for genetic variation analysis, DNA sequencing, and genotyping. Illumina's cutting-edge platforms enable researchers to gain valuable insights into human health and disease, plant and animal genomics, and forensic genomics. With a global presence and a solid track record of delivering high-quality genomic tools, Illumina continues to make significant contributions to the scientific community and shape the future of genomic research.
Illumina Inc has achieved numerous significant milestones. The company revolutionized genetic analysis by developing high-throughput DNA sequencing technologies. It introduced the first commercially available sequencing system, the Genome Analyzer, enabling unprecedented advancements in genomics research. Illumina's innovative technologies have played a pivotal role in driving breakthrough discoveries in fields like cancer research, rare disease diagnosis, and agriculture. The company's contributions have been recognized globally, and it has received various awards and recognitions for its exceptional products and services. Through continuous innovation and strategic collaborations, Illumina Inc remains at the forefront of genomics, continually expanding the boundaries of scientific knowledge.
Illumina Inc is primarily present in various countries and regions worldwide. With its global presence, Illumina serves customers and conducts business operations in North America, Europe, Asia Pacific, and Latin America. The company's headquarters are located in San Diego, California, United States. Illumina has established offices, manufacturing facilities, and collaborations across different nations, including but not limited to the United Kingdom, Germany, Australia, China, Japan, and Brazil. Through its expansive reach and network, Illumina continues to contribute to advancements in genomic research and personalized medicine on a global scale.
Illumina Inc represents values of advancing genomics and enabling researchers to unlock the power of the genome. With a strong corporate philosophy focused on innovation, collaboration, and customer-centricity, Illumina is committed to transforming human health by developing breakthrough technologies in genetic sequencing and analysis. By providing cutting-edge solutions, Illumina empowers scientists and healthcare professionals worldwide to make groundbreaking discoveries and personalized medicine advancements. As a leader in genomics, Illumina Inc strives to drive scientific and clinical progress, ultimately improving lives and shaping the future of genomic medicine.
Analysts currently set an average price target of 200.14 USD for the Illumina stock (median: 210.00 USD), implying -25.4 % versus the latest price. The consensus is based on 28 analyst ratings.
28 analysts currently rate the Illumina stock: 16 recommend buying, 9 holding and 3 selling. For 2026, analysts expect Illumina to generate revenue of 4.62 B USD and earnings per share of 5.42 USD.
Converted at the current exchange rate, the Illumina share trades at 239.24 EUR (268.13 USD).
The Illumina share (ILMN) is listed on 10 stock exchanges, including: NASDAQ (ILMN), London (0J8Z.L), SIX (Zürich) (ILUCHF.SW), XETRA (ILU.DE), Frankfurt (ILU.F), München (ILU.MU), Düsseldorf (ILU.DU), Wien (ILMN.VI).
Illumina Inc. is a US company specializing in the field of genomics research. It was founded in 1998 by four biochemists and is headquartered in San Diego, California. Illumina is positioned as a leading provider of technologies for DNA and RNA sequencing. The company has five core business areas: genomics, oncology, reproductive and gynecology, agriculture, and forensics. Each of these areas has its own range of products and services. The genomics area is Illumina's largest business area and includes a wide range of solutions for DNA sequencing. These include both devices and software solutions for the analysis and interpretation of sequencing data. The oncology business area focuses on the development of diagnostic solutions for cancer. Illumina offers a range of services, including sequencing of tumor and normal tissues to identify genomic changes and make personalized treatment decisions. In the reproductive and gynecology area, Illumina provides solutions for prenatal diagnostics, including sequencing of the fetal genome. The company also has a comprehensive range of products for in vitro fertilization. In the agriculture business, Illumina offers solutions for genomics of livestock and crops. These solutions can be used for breeding livestock and crops to improve their productivity and health. In the forensics area, Illumina provides solutions for the identification and analysis of DNA traces. These solutions can be used for forensic investigations, identification of individuals, and monitoring of animal populations. Some of Illumina's most well-known products are the HiSeq and MiSeq sequencers, which are used for high-throughput sequencing. There are also cloud-based analysis solutions for interpreting the data, as well as solutions for quantitative PCR. Illumina has also focused on partnerships with other major companies. It collaborates with Roche, Qiagen, Pacific Biosciences, and Oxford Nanopore Technologies to expand and enhance its products and services. Overall, Illumina specializes in integrating genomics and bioinformatics solutions to improve the health and well-being of humans, animals, and plants. The company is a key player in the biotechnology industry and is expected to usher in a new era of personalized medicine.
The expected revenue of Illumina is 4.62 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Illumina is 835.26 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Illumina is currently 49.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Illumina stock.
The price-to-sales ratio (P/S) of Illumina is currently 8.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Illumina stock.
The Eulerpool Quality Score for Illumina is 4/10.
The ISIN of Illumina is US4523271090. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Illumina is 927079. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Illumina is ILMN. The ticker symbol is used to trade Illumina shares on the stock exchange.
Illumina stock
Illumina Peer Group
Illumina Ticker
Illumina FIGI
All fundamentals and in-depth analysis of Illumina
Our stock analysis for Illumina stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Illumina. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.